Chronic Renocardiac Syndrome (Type 4 Cardiorenal Syndrome): A Comprehensive Review
Clicks: 1
ID: 314152
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #238 of 254 articles by views in Yemen Journal of Medicine
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 254 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The five-subtype classification of cardiorenal syndrome (CRS), established a decade ago, provides a crucial framework for understanding the interdependent relationship between the heart and kidneys. Chronic renal cardiac syndrome (cRCS), categorized as type 4 CRS, is characterized by primary chronic kidney disease (CKD) that leads to persistent cardiac dysfunction, associated with markedly increased morbidity and mortality rates. The elevated risk is attributed to a multifaceted pathophysiological mechanism wherein advancing renal dysfunction induces metabolic anomalies, persistent inflammation, neurohormonal stimulation, and expedited vascular pathology, culminating in considerable structural harm to the heart. CKD has diverse cardiac effects, including systolic heart failure, diastolic dysfunction, arrhythmias, valvular calcification, and sudden cardiac death. Historically, management focused on support via volume control, dialytic optimization, and neurohormonal blockade. The therapeutic landscape for cRCS has undergone a notable paradigm shift. The use of sodium-glucose cotransporter-2 (SGLT2) inhibitors and non-steroidal mineralocorticoid receptor antagonists (MRAs) as critical, disease-modifying therapies offers a substantial opportunity to improve cardiovascular and renal outcomes. This review, current through December 2025, synthesizes contemporary epidemiology, pathophysiology, and evolving diagnostic approaches for cRCS, with an emphasis on evidencebased treatment strategies. An early and integrated cardiorenal management strategy is crucial for addressing the substantial and growing public health challenge posed by CKD.
| Reference Key |
habas2026chronic1
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Elmukhtar Habas, Ala Habas, Mohamed Bhagi, Eshrak Habas, Amnna Rayani |
| Journal | Yemen Journal of Medicine |
| Year | 2026 |
| DOI |
10.63475/yjm.v5i1.0282
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.